|
US6924123B2
(en)
*
|
1996-10-29 |
2005-08-02 |
Oxford Biomedica (Uk) Limited |
Lentiviral LTR-deleted vector
|
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
|
GB0024550D0
(cg-RX-API-DMAC10.html)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
US6933377B2
(en)
*
|
2002-07-29 |
2005-08-23 |
Qun Chen |
Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response
|
|
EP2354155B1
(en)
*
|
2003-05-16 |
2017-05-03 |
Acorda Therapeutics, Inc. |
Fusion Proteins for Treatment of CNS
|
|
JP2012511033A
(ja)
*
|
2008-12-08 |
2012-05-17 |
テゴファーム コーポレーション |
多価化合物の可逆阻害用マスキングリガンド
|
|
WO2012135389A2
(en)
*
|
2011-03-28 |
2012-10-04 |
The Regents Of The University Of California |
Host cells and methods for oxidizing aromatic amino acids
|
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
JP6698114B2
(ja)
*
|
2011-10-28 |
2020-05-27 |
オックスフォード バイオメディカ （ユーケー） リミテッド |
構築物
|
|
US10400252B2
(en)
*
|
2011-10-28 |
2019-09-03 |
Oxford Biomedica (Uk) Ltd. |
Catecholamine enzyme fusions
|
|
EP4223772A3
(en)
|
2013-02-15 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Optimized factor viii gene
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
SG10201913278PA
(en)
|
2016-02-01 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Optimized factor viii genes
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
FI3525583T3
(fi)
|
2016-10-12 |
2025-10-31 |
Bioverativ Usa Inc |
Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
|
|
AU2017353939B2
(en)
|
2016-11-07 |
2025-01-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2019003165A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
CN111344011B
(zh)
|
2017-06-27 |
2024-01-26 |
纽洛可科学有限公司 |
抗fam19a5抗体用于治疗纤维化的用途
|
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES DIRECTED AGAINST A 19-SEQUENCE-LIKE FAMILY, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
|
|
TWI823868B
(zh)
|
2017-10-11 |
2023-12-01 |
美商生物維瑞提夫美國公司 |
誘導補體活性之方法
|
|
SG11202007114VA
(en)
|
2018-02-01 |
2020-08-28 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii
|
|
EP3823986A4
(en)
|
2018-04-24 |
2022-03-23 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES AGAINST FAMILY SEQUENCE 19, ITEM A5 IN THE TREATMENT OF NEUROPATHIC PAIN
|
|
US11970532B2
(en)
|
2018-05-10 |
2024-04-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
|
US12459995B2
(en)
|
2018-10-16 |
2025-11-04 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies
|
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
|
AU2019393880A1
(en)
|
2018-12-06 |
2021-07-15 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor IX
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
KR20240000655A
(ko)
|
2018-12-27 |
2024-01-02 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
EP3906260A4
(en)
|
2019-01-02 |
2022-08-31 |
Neuracle Science Co., Ltd |
SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5 AND METHOD OF USE THEREOF
|
|
KR20220097891A
(ko)
|
2019-09-30 |
2022-07-08 |
바이오버라티브 테라퓨틱스 인크. |
렌티바이러스 벡터 제형
|
|
KR20220150274A
(ko)
|
2020-01-13 |
2022-11-10 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
|
|
EP4093752A2
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
WO2021158783A1
(en)
|
2020-02-05 |
2021-08-12 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
WO2022087453A1
(en)
|
2020-10-22 |
2022-04-28 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
CA3195594A1
(en)
|
2020-11-05 |
2022-05-12 |
Byung Ha Lee |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
IL311725A
(en)
|
2021-09-30 |
2024-05-01 |
Bioverativ Therapeutics Inc |
Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
|
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
|
KR20240130705A
(ko)
|
2021-12-30 |
2024-08-29 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
|
|
US20250340868A1
(en)
|
2022-07-28 |
2025-11-06 |
Stemcell Technologies Canada Inc. |
Polynucleotides encoding linked antigens and uses thereof
|
|
EP4615485A1
(en)
|
2022-11-07 |
2025-09-17 |
NeoImmuneTech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|